New York: Icon plc (NASDAQ:ICLR) Stock Has Just Had Its “Hold” Rating Reiterated by Mizuho Securities. Shares now Have a $118.0 Target

January 14, 2018 - By Vivian Currie

 New York: Icon plc (NASDAQ:ICLR) Stock Has Just Had Its

Icon plc (NASDAQ:ICLR) Rating Reaffirmed

Recently, In analysts report revealed to investors and clients on Thursday morning, Icon plc (NASDAQ:ICLR) shares have had their “Hold” Rating kept by research analysts at Mizuho Securities, who currently has a $118.0 target price per share on company. This target by Mizuho Securities would suggest the possibile upside of 4.18 % from the last close price.

ICON Public Limited Company (NASDAQ:ICLR) Ratings Coverage

Among 12 analysts covering Icon plc (NASDAQ:ICLR), 8 have Buy rating, 1 Sell and 3 Hold. Therefore 67% are positive. Icon plc has $145.0 highest and $77 lowest target. $120’s average target is 5.94% above currents $113.27 stock price. Icon plc had 32 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of ICON Public Limited Company (NASDAQ:ICLR) earned “Buy” rating by Evercore on Friday, October 14. Mizuho maintained the stock with “Hold” rating in Thursday, October 26 report. Jefferies downgraded ICON Public Limited Company (NASDAQ:ICLR) on Friday, June 3 to “Hold” rating. The stock of ICON Public Limited Company (NASDAQ:ICLR) earned “Hold” rating by SunTrust on Friday, December 16. Robert W. Baird maintained ICON Public Limited Company (NASDAQ:ICLR) on Thursday, October 26 with “Buy” rating. The firm has “Buy” rating by SunTrust given on Monday, July 31. As per Tuesday, June 21, the company rating was initiated by Credit Suisse. SunTrust maintained ICON Public Limited Company (NASDAQ:ICLR) on Monday, October 30 with “Buy” rating. The stock of ICON Public Limited Company (NASDAQ:ICLR) has “Equal-Weight” rating given on Friday, October 27 by Barclays Capital. Jefferies upgraded the shares of ICLR in report on Thursday, June 29 to “Buy” rating.

The stock decreased 1.26% or $1.44 during the last trading session, reaching $113.27. About 235,981 shares traded. ICON Public Limited Company (NASDAQ:ICLR) has risen 40.78% since January 14, 2017 and is uptrending. It has outperformed by 24.08% the S&P500.

Analysts await ICON Public Limited Company (NASDAQ:ICLR) to report earnings on February, 15. They expect $1.41 earnings per share, up 11.90 % or $0.15 from last year’s $1.26 per share. ICLR’s profit will be $76.36M for 20.08 P/E if the $1.41 EPS becomes a reality. After $1.35 actual earnings per share reported by ICON Public Limited Company for the previous quarter, Wall Street now forecasts 4.44 % EPS growth.

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company has market cap of $6.13 billion. The firm specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It has a 21.94 P/E ratio. The Company’s clinical development services comprise product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services.

More recent ICON Public Limited Company (NASDAQ:ICLR) news were published by: which released: “ICON plc (ICLR) Reports FY18 EPS & Revenue Guidance Above Consensus” on January 09, 2018. Also published the news titled: “ICON Appoints Dr. James Cummings as President of ClinicalRM” on January 09, 2018.‘s news article titled: “Icon PLC: A Hidden Gem In An Uncertain Industry” with publication date: August 29, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.